Emergent BioSolutions (EBS) Competitors $8.78 -0.09 (-1.01%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EBS vs. MNKD, CLDX, DVAX, BCRX, NVAX, MYGN, INVA, OPK, IRWD, and SGMOShould you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Myriad Genetics (MYGN), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry. Emergent BioSolutions vs. MannKind Celldex Therapeutics Dynavax Technologies BioCryst Pharmaceuticals Novavax Myriad Genetics Innoviva OPKO Health Ironwood Pharmaceuticals Sangamo Therapeutics Emergent BioSolutions (NYSE:EBS) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Do insiders & institutionals have more ownership in EBS or MNKD? 78.4% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 1.2% of Emergent BioSolutions shares are held by insiders. Comparatively, 3.0% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor EBS or MNKD? In the previous week, MannKind had 8 more articles in the media than Emergent BioSolutions. MarketBeat recorded 13 mentions for MannKind and 5 mentions for Emergent BioSolutions. MannKind's average media sentiment score of 0.75 beat Emergent BioSolutions' score of 0.29 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent BioSolutions 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, EBS or MNKD? MannKind has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent BioSolutions$1.09B0.43-$760.50M-$4.10-2.14MannKind$267.20M6.12-$11.94M$0.0784.71 Is EBS or MNKD more profitable? MannKind has a net margin of 8.07% compared to Emergent BioSolutions' net margin of -18.55%. Emergent BioSolutions' return on equity of -9.91% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Emergent BioSolutions-18.55% -9.91% -3.31% MannKind 8.07%-17.74%8.68% Do analysts rate EBS or MNKD? Emergent BioSolutions presently has a consensus target price of $14.00, suggesting a potential upside of 59.45%. MannKind has a consensus target price of $8.67, suggesting a potential upside of 46.15%. Given Emergent BioSolutions' higher probable upside, equities research analysts plainly believe Emergent BioSolutions is more favorable than MannKind.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent BioSolutions 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more risk & volatility, EBS or MNKD? Emergent BioSolutions has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Does the MarketBeat Community believe in EBS or MNKD? MannKind received 159 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.83% of users gave Emergent BioSolutions an outperform vote while only 60.04% of users gave MannKind an outperform vote. CompanyUnderperformOutperformEmergent BioSolutionsOutperform Votes42166.83% Underperform Votes20933.17% MannKindOutperform Votes58060.04% Underperform Votes38639.96% SummaryMannKind beats Emergent BioSolutions on 13 of the 19 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EBS vs. The Competition Export to ExcelMetricEmergent BioSolutionsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$475.74M$6.86B$5.17B$19.63BDividend YieldN/A3.06%4.78%3.51%P/E Ratio-2.1410.75127.7743.82Price / Sales0.43285.811,261.3917.46Price / Cash9.7556.6541.0421.73Price / Book0.705.394.895.46Net Income-$760.50M$151.81M$119.40M$987.18M7 Day Performance2.09%-5.54%14.54%-2.12%1 Month Performance13.73%0.33%17.43%1.31%1 Year Performance268.91%16.04%35.31%16.44% Emergent BioSolutions Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EBSEmergent BioSolutions4.1767 of 5 stars$8.78-1.0%$14.00+59.5%+268.9%$475.74M$1.09B-2.141,600Insider TradeNews CoverageMNKDMannKind3.5218 of 5 stars$6.38-2.4%$8.67+35.8%+50.5%$1.76B$198.96M93.43400CLDXCelldex Therapeutics3.0636 of 5 stars$26.43+4.0%$62.25+135.5%-29.9%$1.75B$6.88M-9.89160DVAXDynavax Technologies4.8018 of 5 stars$12.98+0.2%$22.00+69.5%-5.6%$1.71B$260.81M100.00408News CoveragePositive NewsBCRXBioCryst Pharmaceuticals3.8591 of 5 stars$7.36-2.3%$15.60+112.0%+21.0%$1.52B$412.58M-12.34530Positive NewsGap DownNVAXNovavax3.8049 of 5 stars$9.28+1.9%$17.83+92.2%+66.7%$1.49B$847.25M-4.031,543MYGNMyriad Genetics4.5662 of 5 stars$14.06-2.6%$24.27+72.6%-33.4%$1.28B$823.60M-11.102,700INVAInnoviva1.9307 of 5 stars$18.59+0.1%N/A+18.6%$1.16B$310.46M26.93112Short Interest ↓Positive NewsOPKOPKO Health4.4663 of 5 stars$1.56-2.2%$2.75+76.8%+4.2%$1.06B$711.41M-8.343,930Positive NewsIRWDIronwood Pharmaceuticals4.1215 of 5 stars$3.52-0.3%$10.40+195.5%-68.3%$563.31M$442.73M-117.67220Gap DownSGMOSangamo Therapeutics1.8787 of 5 stars$2.52+22.7%$7.00+178.3%+579.4%$524.76M$176.23M-3.11480Analyst UpgradeGap Down Related Companies and Tools Related Companies MNKD Alternatives CLDX Alternatives DVAX Alternatives BCRX Alternatives NVAX Alternatives MYGN Alternatives INVA Alternatives OPK Alternatives IRWD Alternatives SGMO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:EBS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EBS Stock Alerts